LONG-TERM EFFICACY AND SAFETY OF SIRUKUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE ANTI-TUMOR NECROSIS FACTOR THERAPY: RESULTS OF THE RANDOMIZED, PHASE 3 SIRROUND-T STUDY

被引：0
|
作者：
Tanaka, Y. [1 ]
Aletaha, D. [2 ]
Agarwal, P. [3 ]
Kurrasch, R. [4 ]
Tak, P. P. [5 ]
Popik, S. [3 ]
机构：
[1] Univ Occupat & Environm Hlth, Dept Internal Med, Kitakyushu, Fukuoka, Japan
[2] Med Univ Vienna, Div Rheumatol, Vienna, Austria
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Stevenage, Herts, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.6486
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0214
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [41] Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis
    Takeuchi, Tsutomu
    Kawanishi, Masafumi
    Nakanishi, Megumi
    Yamasaki, Hironori
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 (11) : 1776 - 1785
  • [42] Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-α treatment
    Higashida, J
    Wun, T
    Schmidt, S
    Naguwa, SM
    Tuscano, JM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (11) : 2109 - 2115
  • [43] Golimumab, a New Human Anti-Tumor Necrosis Factor α Antibody, Administered Intravenously in Patients With Active Rheumatoid Arthritis Forty-Eight-Week Efficacy and Safety Results of a Phase III Randomized, Double-Blind, Placebo-Controlled Study
    Kremer, Joel
    Ritchlin, Christopher
    Mendelsohn, Alan
    Baker, Daniel
    Kim, Lilianne
    Xu, Zhenhua
    Han, John
    Taylor, Peter
    ARTHRITIS AND RHEUMATISM, 2010, 62 (04): : 917 - 928
  • [44] Long-Term Real-Life Experience With Rituximab in Adult Finnish Patients With Rheumatoid Arthritis Refractory or With Contraindication to Anti-Tumor Necrosis Factor Drugs
    Valleala, Heikki
    Korpela, Markku
    Hienonen-Kempas, Tuija
    Immonen, Kai
    Lahteenmaki, Jukka
    Uusitalo, Tea
    Komulainen, Riitta
    Mottonen, Timo
    Hannonen, Pekka
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2015, 21 (01) : 24 - 30
  • [45] Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
    Conaghan, PG
    Quinn, MA
    O'Connor, P
    Wakefield, RJ
    Karim, Z
    Emery, P
    ARTHRITIS AND RHEUMATISM, 2002, 46 (07): : 1971 - 1972
  • [46] Bone Resorption, OsteoClastogenesis and Adalimumab. A Study On the Impact of Anti-Tumor Necrosis Factor Therapy On Osteoclastogenesis In Patients with Rheumatoid Arthritis
    Guay-Belanger, Sabrina
    Fernandes, Arthur J.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S470 - S470
  • [47] The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register - Rheumatoid Arthritis.
    Mercer, Louise K.
    Lunt, Mark
    Low, Audrey S.
    Galloway, James B.
    Watson, Kath
    Dixon, William G.
    Symmons, Deborah P.
    Hyrich, Kimme L.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S680 - S680
  • [48] FINAL 5-YEAR SAFETY AND EFFICACY RESULTS OF A PHASE 3, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE
    Keystone, Edward
    Genovese, Mark C.
    Hall, Stephen
    Miranda, Pedro C.
    Bae, Sang-Cheol
    Han, Chenglong
    Gathany, Tim
    Zhou, Yiying
    Xu, Stephen
    Hsia, Elizabeth C.
    RHEUMATOLOGY, 2014, 53 : 99 - 99
  • [49] Long-Term Effect of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, on Radiographic Progression in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global Phase 3 Trial
    Karpouzas, George
    Takeuchi, Tsutomu
    Thorne, Carter
    Sheng, Shihong
    Kurrasch, Regina
    Fei, Kaiyin
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [50] Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis -: Results from a large UK national cohort study
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Silman, Alan J.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (01): : 13 - 20
12345